Table 1 The baseline demographics and clinical characteristics between rivaroxaban and LMWH in the dataset by propensity score matching
Characteristics | Before propensity score matchinga | After propensity score matchinga | ||||
|---|---|---|---|---|---|---|
Rivaroxaban, No. (%) (N = 216) | LMWH, No. (%) (N = 230) | Standardized mean differenceb | Rivaroxaban, No. (%) (N = 191) | LMWH, No. (%) (N = 191) | Standardized mean differenceb | |
Demographics | ||||||
Mean age (25%,75%), yearsc | 65 (61,71) | 65 (59, 70) | / | 65 (61, 72) | 64 (59, 70) | / |
Age ≥ 75y | 27 (12.5) | 35 (15.2) | -0.0822 | 26 (13.6) | 24 (12.6) | 0.0317 |
Gender, female | 91 (42.1) | 101 (43.9) | -0.0361 | 85 (44.5) | 85 (44.5) | 0.0000 |
Histopathology of cancer | ||||||
Adenocarcinoma | 170 (78.7) | 185 (80.4) | -0.0423 | 154 (80.6) | 149 (78.0) | 0.0639 |
Squamous cell carcinoma | 28 (13.0) | 29 (12.6) | 0.0105 | 23 (12.0) | 28 (14.7) | -0.0779 |
Small cell lung cancer | 6 (2.8) | 4 (1.8) | 0.0632 | 4 (2.1) | 2 (1.0) | 0.0637 |
Others | 12 (5.5) | 12 (5.2) | 0.0148 | 10 (5.3) | 12 (6.3) | -0.0457 |
Cancer stage | ||||||
I | 22 (10.2) | 14 (6.1) | 0.1355 | 17 (8.9) | 12 (6.3) | 0.0866 |
II | 8 (3.7) | 10 (4.3) | -0.0341 | 8 (4.2) | 10 (5.2) | -0.0554 |
III | 28 (13.0) | 31 (13.5) | -0.0153 | 23 (12.0) | 26 (13.6) | -0.0468 |
IV | 158 (73.1) | 175 (76.1) | -0.0663 | 143 (74.9) | 143 (74.9) | 0.0000 |
Type of index PEd | ||||||
Bilateral PE | 117 (54.2) | 118 (51.3) | 0.0574 | 100 (52.4) | 95 (49.7) | 0.0525 |
Central PE | 49 (22.7) | 70 (30.4) | -0.1850 | 46 (24.1) | 49 (25.7) | -0.0375 |
Multiple sites of PE | 188 (87.0) | 191 (83.0) | 0.1189 | 164 (85.9) | 159 (83.3) | 0.0779 |
Risk stratification of PEd | ||||||
Low | 171 (79.2) | 169 (73.5) | 0.1401 | 148 (77.5) | 142 (74.4) | 0.0774 |
Low to intermediate | 35 (16.2) | 50 (21.7) | -0.1502 | 33 (17.3) | 40 (20.9) | -0.0995 |
Intermediate to high | 10 (4.6) | 11 (4.8) | -0.0073 | 10 (5.2) | 9 (4.7) | 0.0249 |
Type of index DVTd | ||||||
Distal DVT | 60 (27.8) | 49 (21.3) | 0.1445 | 50 (26.2) | 46 (24.1) | 0.0468 |
Proximal DVT | 26 (12.0) | 28 (12.2) | -0.0042 | 21 (11.0) | 26 (13.6) | -0.0805 |
None | 130 (60.2) | 153 (66.5) | -0.1294 | 120 (62.8) | 119 (62.3) | 0.0107 |
Platelet count, per μl | ||||||
> 100,000 | 208 (96.3) | 222 (96.5) | -0.0119 | 187 (97.9) | 186 (97.4) | 0.0277 |
50,000–100,000 | 8 (3.7) | 8 (3.5) | 0.0119 | 4 (2.1) | 5 (2.6) | -0.0277 |
< 50,000 | 0 | 0 | / | 0 | 0 | / |
Creatinine clearance, ml/min | ||||||
> 60 | 196 (90.8) | 210 (91.3) | -0.0194 | 172 (90.1) | 172 (90.1) | 0.0000 |
≤ 60 | 20 (10.2) | 20 (8.7) | 0.0194 | 19 (9.9) | 19 (9.9) | 0.0000 |
Time from first cancer diagnosis to index PE, yeare | ||||||
< 0.5 | 138 (63.9) | 128 (55.7) | 0.1715 | 121 (63.4) | 118 (61.8) | 0.0327 |
0.5–1 | 15 (6.9) | 21 (9.1) | -0.0860 | 13 (6.8) | 18 (9.4) | -0.1000 |
> 1 | 63 (29.2) | 81 (35.2) | -0.1331 | 57 (29.8) | 55 (28.8) | 0.0230 |
Active anticancer treatmentf | ||||||
Chemotherapy | 65 (30.1) | 64 (27.8) | 0.0494 | 53 (27.7) | 51 (26.7) | 0.0228 |
Targeted therapy | 42 (19.4) | 55 (23.9) | -0.1129 | 38 (19.9) | 44 (23.1) | -0.0794 |
Immunotherapy | 8 (3.7) | 6 (2.6) | 0.0580 | 8 (4.2) | 5 (2.6) | 0.0832 |
Others | 101 (46.8) | 105 (45.7) | 0.0222 | 92 (48.2) | 91 (47.6) | 0.0105 |
Charlson comorbidity index score | ||||||
0 | 0 | 0 | / | 0 | 0 | / |
1–2 | 32 (14.8) | 26 (11.3) | 0.0988 | 27 (14.1) | 24 (12.0) | 0.0590 |
≥ 3 | 184 (85.2) | 204 (88.7) | -0.1294 | 164 (85.9) | 166 (88.0) | -0.0442 |
Medications | ||||||
Antiplatelet useg | 15 (6.9) | 14 (6.1) | 0.0337 | 12 (6.3) | 13 (6.8) | -0.0206 |
NSAIDs | 29 (13.4) | 35 (15.2) | -0.0525 | 27 (14.1) | 24 (12.6) | 0.0461 |
Corticosteroids | 21 (9.7) | 17 (7.4) | 0.0787 | 17 (8.9) | 15 (7.9) | 0.0353 |